| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Articles |
Departments of Medicine and Pathology, University of Birmingham, Queen Elizabeth Hospital (A.J.H.), Edgbaston, Birmingham, United Kingdom B15 2TH; and the Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center (W.E.R.), Dallas, Texas 75235-7200
Address all correspondence and requests for reprints to: Prof. Paul M. Stewart, M.D., F.R.C.P., Department of Medicine, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom B15 2TH. E-mail: p.m.stewart{at}bham.ac.uk
Abstract
Two isozymes of 11ß-hydroxysteroid dehydrogenase (11ßHSD) catalyze the interconversion of hormonally active cortisol to inactive cortisone. Activity and messenger ribonucleic acid studies indicate that type 1 11ßHSD (11ßHSD1) is expressed in glucocorticoid target tissues such as liver, gonad, and cerebellum, where it regulates the exposure of cortisol to glucocorticoid receptors. To further understand the role of 11ßHSD1 in human tissues, we have studied the localization of this isozyme using an antibody raised in sheep against amino acids 19–33 of human 11ßHSD1. Western blot analyses indicated that the immunopurified antibody recognized a band of approximately 34 kDa in human liver and decidua. Immunoperoxidase studies on liver, adrenal, ovary, decidua, and adipose tissue indicated positive cytoplasmic staining for 11ßHSD1. 11ßHSD1 immunoreactivity was observed more intensely around the hepatic central vein, with no staining around the portal vein, hepatic artery, or bile ducts. No staining for 11ßHSD1 was observed in the adrenal medulla, but 11ßHSD1-immunoreactive protein was observed in all three zones of the adrenal cortex, with the most intense staining in the zona reticularis > zona glomerulosa > zona fasciculata. In the human ovary, immunoreactivity was observed in the developing oocyte and the luteinized granulosa cells of the corpus luteum. No staining was observed in granulosa cells, thecal cells, or ovarian stroma, which contrasted with the marked expression of 11ßHSD2 in the granulosa cell layer. Sections of human decidua showed high expression of 11ßHSD1 in decidual cells. In omental adipose tissue, 11ßHSD1 immunoreactivity was observed in both stromal and adipocyte cells. Immunohistochemical localization of 11ßHSD1 in human liver, adrenal, ovary, decidua, and adipose tissue using this novel antiserum provides us with a tool to investigate the role of this isozyme in modulating glucocorticoid hormone action within these tissues.
IN MAN, two distinct isozymes of the enzyme 11ß-hydroxysteroid dehydrogenase (11ßHSD) catalyze the interconversion of hormonally active cortisol (Kendall’s compound F) to the inactive 11-keto metabolite cortisone (compound E) (1, 2). The type 1 isozyme of 11ßHSD (11ßHSD1) is a low affinity NADP/NADPH-dependent dehydrogenase/oxo-reductase, with an apparent Km for F of 2.1 µmol/L, and for E of 0.3 µmol/L (3). In keeping with these kinetic data, the predominant role of this isozyme in vivo has been shown to be 11-oxo-reduction, i.e. the generation of active glucocorticoid (4, 5). In contrast, type 2 11ßHSD (11ßHSD2) is a high affinity, unidirectional, NAD-dependent dehydrogenase with an apparent Km for F of 50 nmol/L (2, 3, 6). It is this isozyme that is found principally in mineralocorticoid target tissues such as the kidney and colon, where it protects the mineralocorticoid receptor from cortisol excess. Mutations in the gene encoding this isozyme of 11ßHSD are responsible for a heritable form of hypertension, apparent mineralocorticoid excess (7, 8, 9), in which cortisol acts as a potent mineralocorticoid.
The distribution and localization of 11ßHSD1 within tissues have been extensively studied in the rat (10). In human tissues, RT-PCR, enzyme activity studies, and Northern analyses have localized 11ßHSD1 to glucocorticoid target tissues, such as liver, lung, gonad, cerebellum, and pituitary (1, 11). However, largely due to the lack of specific antisera against human 11ßHSD1, the localization of this isozyme within these target tissues remains unknown.
We now report on the characterization of an antibody against human 11ßHSD1 and describe the localization of this isozyme of 11ßHSD within human liver, adrenal, ovary, decidua, and adipose tissue.
Materials and Methods
Tissue samples
Tissues were obtained in accordance with local ethical committee approval. Adult human liver, adrenal, and adipose tissues were obtained from the Department of Pathology, University of Birmingham (Birmingham, UK). In every case, tissues had been obtained from operative samples (usually partial hepatectomies, normal adrenals at the time of harvesting donor kidneys, and operative adipose tissue samples) and were histologically normal. Samples of normal human ovary and decidua were also obtained from operative samples from the Birmingham Womens’ Hospital. In each case a minimum of six separate normal tissues were studied, and the results were shown to be consistent.
Synthesis of a human 11ßHSD1 antibody
Using hydrophilicity profiles, one region (amino acids 19–33) was selected from the published amino acid sequence of the human type 1 isozyme of 11ßHSD (1). This sequence was synthesized as an eight-branched multiantigenic peptide, mixed with Freund’s complete adjuvant, and used to immunize a single sheep. An IgG fraction was prepared from the immune serum by ammonium sulfate precipitation and ion exchange chromatography.
Immunohistochemistry
Five-micron thick formalin-fixed sections of normal liver, adrenal, ovary, decidua and adipose tissue were cut and placed on coated glass slides (Fro-Tissuer pen, The Binding Site, Birmingham, UK). After dewaxing, slides were treated with methanol-hydrogen peroxide (1:1000) to block endogenous peroxidase activity. After washing in phosphate-buffered saline (PBS; 0.05 mol/L; pH 7.6), slides were incubated with polyclonal antibody to human 11ßHSD1 (liver, ovary, decidua, and adipose tissue at a dilution of 1:100; adrenal at a dilution of 1:200) in 10% normal swine serum for 1 h at room temperature. Control sections included 1) omission of primary antibody; 2) use of primary antibody preabsorbed with the immunizing peptide at a dilution of 1:500, prepared as described previously (12); and 3) tissues known to be negative for 11ßHSD1 expression, for example term placenta. In addition, for the human ovary experiments, immunohistochemical studies were undertaken using an in-house antibody against human 11ßHSD2 (at a dilution of 1:50) (12). Secondary antibody, donkey antisheep IgG peroxidase conjugate (1:400), was added to sections for 30 min. Slides were developed using 3,3'-diaminobenzidine and were counterstained with Mayer’s hematoxylin.
Western analysis
Western analysis was performed by SDS-PAGE on discontinuous acrylamide gels as previously described (12). Briefly, samples were prepared for loading by denaturing at 95 C in 2% SDS, 10% glycerol, 62.5 mmol/L Tris (pH 6.8), and 0.1% dithiothreitol and electrophoresed at 200 V through 4.5% stacking and 10% resolving gels using the Mini-Protean II Western apparatus (Bio-Rad, Richmond, CA). Ten micrograms of total protein from human liver, decidua, and placenta were loaded per lane, and prestained molecular weight markers (Sigma Chemical Co., Poole, UK) were run in parallel lanes. After electrophoresis, proteins were transferred to Immobilon-P membrane (0.4 µm; Millipore Corp., Bedford, MA), and membranes were blocked for nonspecific binding with 20% nonfat milk-PBS-0.1% Tween-20, then washed briefly in PBS-Tween-20 solution. Membranes were incubated with polyclonal antibody to human 11ßHSD1 at a dilution of 1:1,000 (overnight at 4 C), washed with PBS-0.1% Tween-20, and incubated with donkey antisheep IgG peroxidase-conjugated secondary antibody at a dilution of 1:75,000 for 1.5 h at room temperature. Membranes were washed, and protein bands were visualized using the ECL detection kit (Amersham International, Aylesbury, UK) by exposing membranes to x-ray film (DuPont, Stevenage, UK) for 1–10 min. Western blot analysis was also performed using the primary antibody preabsorbed with a 1:500 dilution of the immunizing peptide to demonstrate specificity for 11ßHSD1.
Results
Western blot analysis indicated a band of approximately 34 kDa in
both liver and decidua, in keeping with the predicted size of
11ßHSD1. No band was observed in human placenta. A second band
corresponding to approximately 68 kDa was consistently observed in
human liver. No bands were seen when Western analysis was carried out
using primary antibody preabsorbed with the immunizing peptide
(dilution, 1:500; Fig. 1
).
|
). On
higher magnification, the staining of 11ßHSD1 was found to be purely
cytoplasmic (Fig. 2b). No staining was observed when the antibody was
preabsorbed with the immunizing peptide at a dilution of 1:500 (data
not shown).
|
).
Staining intensity appeared to be highest in the zona reticularis
> zona glomerulosa > zona fasciculata.
|
shows a
group of primordial follicles within the human ovary; the surrounding
stroma and the flattened follicular cells surrounding the oocyte were
negative for 11ßHSD1, whereas the oocyte expressed
11ßHSD1-immunoreactive protein. As the primordial follicle developed
into a primary follicle, the follicular cells proliferated, but these
cells and the surrounding thecal cells remained negative for 11ßHSD1
expression, although the oocyte continued to express 11ßHSD1 (Fig. 4b). In the mature preovulatory follicle, no 11ßHSD1 immunoreactivity
was observed in the thecal or granulosa cells (Fig. 4c), in contrast to
11ßHSD2 immunoreactivity, which was clearly evident in these two cell
layers (Fig. 4d). After ovulation, the luteinized granulosa cells
expressed high levels of 11ßHSD1 (Fig. 4e). The specificity of the
signal was confirmed using the primary antibody preabsorbed with the
immunizing peptide at a dilution of 1:500 (Fig. 4f).
|
) and human omental adipose tissue,
where immunoreactivity was localized to both stromal cells and the
cytoplasm of differentiated adipocytes (Fig. 6).
|
|
The isozymes of 11ßHSD play a crucial role in modulating corticosteroid hormone action at a prereceptor level. Although 11ßHSD1 was the first enzyme to be characterized and cloned in rodent and human tissues (1, 13), there has been recent interest in the 11ßHSD2 isozyme (2), principally because of its role in protecting the mineralocorticoid receptor from cortisol excess (14, 15) and its association with human hypertension (7, 8, 9). Several studies, however, have indicated that 11ßHSD1 regulates glucocorticoid hormone action in key tissues, such as the liver, gonad, pituitary, brain, and adipose tissue (4, 16, 17, 18, 19, 20). Although 11ßHSD1 activity is bidirectional, at least in tissue homogenates with exogenous cofactor added, 11ßHSD1 is predominantly an oxo-reductase in intact cell assays (3, 4, 5), generating the active glucocorticoids, cortisol and corticosterone, from their inactive 11-oxo metabolites. The development of a specific antiserum against human 11ßHSD1 has enabled us to define the localization of this isozyme within human liver, adrenal, ovary, decidua, and adipose tissue, tissues that have been shown to express 11ßHSD1 using enzyme activity/messenger ribonucleic acid (mRNA) studies. The specificity of the antiserum was confirmed by demonstrating hybridization to a 34-kDa band, in keeping with the predicted size of human 11ßHSD1, in both human liver and decidua. A second band corresponding to approximately 68 kDa was consistently observed in human liver, suggesting that the enzyme may also exist as a dimer in this tissue. Neither the 34-kDa nor the 68-kDa band was observed if the antiserum was preabsorbed with the immunizing peptide.
In the liver, 11ßHSD1 expression was observed in hepatocytes radiating outward from the central vein, with no expression around the portal vein, hepatic artery, or bile ducts. The liver is a continually regenerating organ, with migration of hepatocytes from the portal triad toward the central vein upon differentiation (21), and it is possible that 11ßHSD1 expression is closely linked with hepatocyte maturation. Functionally, glucocorticoids and 11ßHSD1 activity are known to regulate gluconeogenesis within the liver, principally through the rate-limiting enzyme phosphoenolpyruvate carboxykinase (4). Clinically, after an oral dose of cortisone acetate, cortisol rapidly appears in the peripheral circulation (22), in keeping with localization of the type 1 isozyme to hepatocytes around the central vein.
Perhaps more puzzling is the expression of 11ßHSD1 in the adult human adrenal, with 11ßHSD1 immunoreactivity present in the zona reticularis and less expression in the zona glomerulosa and zona fasciculata. Although it is possible that the apparent reduced staining in the zona fasciculata reflects an artifact caused by the intense lipid content of this zone of the adrenal cortex, these studies are in keeping with our earlier observations in the rat adrenal (23), where we documented 11ßHSD1 expression in the zona reticularis. Although glucocorticoid and mineralocorticoid receptors have been observed in the human adrenal cortex, the roles of these receptors and 11ßHSD1 in adrenocortical function are unknown. In the zona reticularis, 11ßHSD1 may maintain high glucocorticoid concentrations at the cortico-medullary junction required for the induction of phenylethyl N-methyl transferase and adrenaline synthesis (24). In the rat zona glomerulosa, it has been suggested that cortisol may inhibit aldosterone formation (25), but such studies need to be confirmed in man.
In human ovary, expression of 11ßHSD1 was seen in the oocyte and luteinized granulosa cells of the corpus luteum, but no expression was found in the follicular, granulosa, or thecal cells of the preovulatory follicle. This contrasted with 11ßHSD2 immunoreactivity, which was localized to the preovulatory granulosa and thecal cells. Expression of 11ßHSD1 in the oocyte and corpus luteum has been demonstrated previously in the rat ovary (26); subsequently, Michael et al. (27) showed that human luteinized granulosa cells express 11ßHSD1 mRNA and activity. Tetsuka et al. (28) have recently shown that human preovulatory granulosa cells express 11ßHSD2 mRNA, and that the corpus luteum expresses 11ßHSD1 mRNA. These data suggest that luteinization switches on the expression of 11ßHSD1 in the second half of the ovarian cycle. Why the corpus luteum, whose main product is progesterone, should express an enzyme whose main role is to generate glucocorticoid is unclear. One possibility may be that cortisol generated in situ inhibits LH-stimulated steroidogenesis in the luteinized granulosa cells (27). Alternatively, the role of ovarian 11ßHSD1 may relate not to glucocorticoid, but to the metabolism of progesterone. Earlier studies showed that 11-hydroxylated progesterone derivatives have a higher specific activity for 11ßHSD than cortisol itself (29), suggesting that the preferred substrate for 11ßHSD1 may be progesterone or its derivatives. It is unlikely that 11-hydroxylated progesterone derivatives are present in the ovary, as the ovary does not express 11ß-hydroxylase, but progesterone itself may be metabolized by 11ßHSD1, although this has yet to be demonstrated. Other 11-oxo-steroids, such as 11ß-hydroxyandrostenedione, are known to be present in follicular fluid (30), and these could also be putative substrates for 11ßHSD1. If cortisone is the endogenous substrate, these studies would suggest that cortisol is critical for maturation of the oocyte, and further studies are required to address the issue of 11ßHSD isozyme expression and the outcome of in vitro fertilization-embryo transfer techniques (31).
Human decidual cells, formed from endometrial stromal cells after implantation of the blastocyst, express abundant levels of 11ßHSD1, in keeping with the findings of earlier mRNA and activity studies (32, 33). The developing blastocyst is semiallogenic and is at risk of immune rejection. Local immunosuppressive activity exists within the decidua (34), and cortisol, via 11ßHSD1 expression, may modulate this by inhibiting the production of antiinflammatory cytokines, such as IL-1 (35).
Finally, as exemplified in patients with Cushing’s syndrome and in patients treated with corticosteroids, adipose tissue is an important glucocorticoid target tissue. The glucocorticoid receptor is known to be expressed at this site (36), and glucocorticoids exert profound effects on adipocyte function and differentiation (37). Immunolocalization of 11ßHSD1 within omental adipose tissue is in keeping with our recent mRNA/activity studies in which we suggested that this isozyme may play a pivotal role in regulating glucocorticoid-mediated adipocyte differentiation and function, with obvious ramifications for the pathogenesis of central obesity (20).
In summary, a novel antiserum against 11ßHSD1 has provided us with further information about intracrine control of glucocorticoid action within key human glucocorticoid target tissues. The oxo-reductase activity of this isozyme, generating cortisol from cortisone, suggests important functional roles for glucocorticoid at these sites, with the regulation of 11ßHSD1 expression within these tissues being a key modulator of glucocorticoid hormone action.
Acknowledgments
We thank A. R. Bradwell and G. Mead for assistance in raising the antihuman 11ßHSD1 antibody; Dr. S. R. Ferryman and Mrs. D. Gill, Birmingham Womens’ Hospital, for provision of ovarian and decidual sections; and Mrs. A. Williams, Liver Research Laboratories, for helpful assistance.
Footnotes
1 This work was supported by the Medical Research Council
(G116/72). 
2 Medical Research Council Senior Clinical Fellow.
Received September 18, 1997.
Revised December 17, 1997.
Accepted December 19, 1997.
References
This article has been cited by other articles:
 |
|
 |
|
  A. E. Michael and A. T. Papageorghiou Potential significance of physiological and pharmacological glucocorticoids in early pregnancy Hum. Reprod. Update, September 1, 2008; 14(5): 497 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Hardy, E H Rabbitt, A Filer, P Emery, M Hewison, P M Stewart, N J Gittoes, C D Buckley, K Raza, and M S Cooper Local and systemic glucocorticoid metabolism in inflammatory arthritis Ann Rheum Dis, September 1, 2008; 67(9): 1204 - 1210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Bujalska, K. N. Hewitt, D. Hauton, G. G. Lavery, J. W. Tomlinson, E. A. Walker, and P. M. Stewart Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue Endocrinology, May 1, 2008; 149(5): 2584 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gomez-Sanchez, D. G. Romero, A. F. de Rodriguez, M. P. Warden, Z. Krozowski, and C. E. Gomez-Sanchez Hexose-6-Phosphate Dehydrogenase and 11{beta}-Hydroxysteroid Dehydrogenase-1 Tissue Distribution in the Rat Endocrinology, February 1, 2008; 149(2): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Myers, M. C. Lamont, S. van den Driesche, N. Mary, K. J. Thong, S. G. Hillier, and W. C. Duncan Role of Luteal Glucocorticoid Metabolism during Maternal Recognition of Pregnancy in Women Endocrinology, December 1, 2007; 148(12): 5769 - 5779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chan, E. H Rabbitt, B. A Innes, J. N Bulmer, P. M Stewart, M. D Kilby, and M. Hewison Glucocorticoid-induced apoptosis in human decidua: a novel role for 11{beta}-hydroxysteroid dehydrogenase in late gestation J. Endocrinol., October 1, 2007; 195(1): 7 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Walker, A. Ahmed, G. G. Lavery, J. W. Tomlinson, S. Y. Kim, M. S. Cooper, J. P. Ride, B. A. Hughes, C. H. L. Shackleton, P. McKiernan, et al. 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function J. Biol. Chem., September 14, 2007; 282(37): 27030 - 27036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sunak, D. F Green, L. R Abeydeera, L. M Thurston, and A. E Michael Implication of cortisol and 11{beta}-hydroxysteroid dehydrogenase enzymes in the development of porcine (Sus scrofa domestica) ovarian follicles and cysts Reproduction, June 1, 2007; 133(6): 1149 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L M Thurston, D R E Abayasekara, and A E Michael 11{beta}-Hydroxysteroid dehydrogenase expression and activities in bovine granulosa cells and corpora lutea implicate corticosteroids in bovine ovarian physiology J. Endocrinol., May 1, 2007; 193(2): 299 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Qi and B. Rodrigues Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E654 - E667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Jonas, C. Chandras, D. R. E. Abayasekara, and A. E. Michael Role for Prostaglandins in the Regulation of Type 1 11{beta}-Hydroxysteroid Dehydrogenase in Human Granulosa-Lutein Cells Endocrinology, December 1, 2006; 147(12): 5865 - 5872. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Basu, D. S. Edgerton, R. J. Singh, A. Cherrington, and R. A. Rizza Splanchnic Cortisol Production in Dogs Occurs Primarily in the Liver: Evidence for Substantial Hepatic Specific 11{beta} Hydroxysteroid Dehydrogenase Type 1 Activity Diabetes, November 1, 2006; 55(11): 3013 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Mariniello, V. Ronconi, S. Rilli, P. Bernante, M. Boscaro, F. Mantero, and G. Giacchetti Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome Eur. J. Endocrinol., September 1, 2006; 155(3): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Narvekar, H. O.D. Critchley, L. Cheng, and D. T. Baird Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor Hum. Reprod., September 1, 2006; 21(9): 2312 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. U Onyimba, N. Vijapurapu, S J. Curnow, P. Khosla, P. M Stewart, P. I Murray, E. A Walker, and S. Rauz Characterisation of the prereceptor regulation of glucocorticoids in the anterior segment of the rabbit eye. J. Endocrinol., August 1, 2006; 190(2): 483 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Murphy, R. Smith, W. B. Giles, and V. L. Clifton Endocrine Regulation of Human Fetal Growth: The Role of the Mother, Placenta, and Fetus Endocr. Rev., April 1, 2006; 27(2): 141 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. McCormick, X. Wang, and G. J. Mick Evidence That the 11 {beta}-Hydroxysteroid Dehydrogenase (11 {beta}-HSD1) Is Regulated by Pentose Pathway Flux: STUDIES IN RAT ADIPOCYTES AND MICROSOMES J. Biol. Chem., January 6, 2006; 281(1): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Draper and P. M Stewart 11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action J. Endocrinol., August 1, 2005; 186(2): 251 - 271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J Bujalska, N. Draper, Z. Michailidou, J. W Tomlinson, P. C White, K. E Chapman, E. A Walker, and P. M Stewart Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11{beta}-hydroxysteroid dehydrogenase type 1 J. Mol. Endocrinol., June 1, 2005; 34(3): 675 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Giavoli, R. Libe, S. Corbetta, E. Ferrante, A. Lania, M. Arosio, A. Spada, and P. Beck-Peccoz Effect of Recombinant Human Growth Hormone (GH) Replacement on the Hypothalamic-Pituitary-Adrenal Axis in Adult GH-Deficient Patients J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5397 - 5401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, E. A. Walker, I. J. Bujalska, N. Draper, G. G. Lavery, M. S. Cooper, M. Hewison, and P. M. Stewart 11{beta}-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response Endocr. Rev., October 1, 2004; 25(5): 831 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kannisto, K. H. Pietilainen, E. Ehrenborg, A. Rissanen, J. Kaprio, A. Hamsten, and H. Yki-Jarvinen Overexpression of 11{beta}-Hydroxysteroid Dehydrogenase-1 in Adipose Tissue Is Associated with Acquired Obesity and Features of Insulin Resistance: Studies in Young Adult Monozygotic Twins J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4414 - 4421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Seckl, N. M. Morton, K. E. Chapman, and B. R. Walker Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue Recent Prog. Horm. Res., January 1, 2004; 59(1): 359 - 393. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Liu, D. M. Hawkins, S. Ghosh, and S. S. Young Robust singular value decomposition analysis of microarray data PNAS, November 11, 2003; 100(23): 13167 - 13172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.M. Thurston, D.P. Norgate, K.C. Jonas, L. Gregory, P.J. Wood, B.A. Cooke, and A.E. Michael Ovarian modulators of type 1 11{beta}-hydroxysteroid dehydrogenase (11{beta}HSD) activity and intra-follicular cortisol:cortisone ratios correlate with the clinical outcome of IVF Hum. Reprod., August 1, 2003; 18(8): 1603 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, N. Crabtree, P. M. S. Clark, G. Holder, A. A. Toogood, C. H. L. Shackleton, and P. M. Stewart Low-Dose Growth Hormone Inhibits 11{beta}-Hydroxysteroid Dehydrogenase Type 1 but Has No Effect upon Fat Mass in Patients with Simple Obesity J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2113 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mune, H. Morita, T. Suzuki, Y. Takahashi, Y. Isomura, T. Tanahashi, H. Daido, N. Yamakita, T. Deguchi, H. Sasano, et al. Role of Local 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Expression in Determining the Phenotype of Adrenal Adenomas J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 864 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shafqat, B. Elleby, S. Svensson, J. Shafqat, H. Jornvall, L. Abrahmsen, and U. Oppermann Comparative Enzymology of 11beta -Hydroxysteroid Dehydrogenase Type 1 from Glucocorticoid Resistant (Guinea Pig) Versus Sensitive (Human) Species J. Biol. Chem., January 10, 2003; 278(3): 2030 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Tiosano, I. Eisentein, D. Militianu, G. P. Chrousos, and Z.'e. Hochberg 11{beta}-Hydroxysteroid Dehydrogenase Activity in Hypothalamic Obesity J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 379 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Friedberg, E. Zoumakis, N. Hiroi, T. Bader, G. P. Chrousos, and Z.'e. Hochberg Modulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Mature Human Subcutaneous Adipocytes by Hypothalamic Messengers J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 385 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Tomlinson, B. Sinha, I. Bujalska, M. Hewison, and P. M. Stewart Expression of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue Is Not Increased in Human Obesity J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5630 - 5635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Diederich, E. Eigendorff, P. Burkhardt, M. Quinkler, C. Bumke-Vogt, M. Rochel, D. Seidelmann, P. Esperling, W. Oelkers, and V. Bahr 11{beta}-Hydroxysteroid Dehydrogenase Types 1 and 2: An Important Pharmacokinetic Determinant for the Activity of Synthetic Mineralo- and Glucocorticoids J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5695 - 5701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Draper, S. M. Echwald, G. G. Lavery, E. A. Walker, R. Fraser, E. Davies, T. I. A. Sorensen, A. Astrup, J. Adamski, M. Hewison, et al. Association Studies between Microsatellite Markers within the Gene Encoding Human 11{beta}-Hydroxysteroid Dehydrogenase Type 1 and Body Mass Index, Waist to Hip Ratio, and Glucocorticoid Metabolism J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4984 - 4990. [Abstract] [Full Text] [PDF]
|
|
